The Big Reveal: The Launch of NexOptic Technologies Flat Lens Telescope Prototype

When you make the unbelievable believable, you change perception. But when you make the unreal a reality, you change the world. Last week, the Daguela brothers made history. Today, I present you with the updated story of NexOptic Technology Corp. and its flat lens telescope prototype – a small tribute for those who could not attend the official launch event.…

NexOptic Initiates Development of Telephoto Imaging System for Mobile Devices

NexOptic Technology Corp. (OTCQB: NXOPF) (TSX VENTURE: NXO) (FRANKFURT: E301) (BERLIN: E301) and Spectrum Optix Inc. of Calgary, Canada announces they have initiated an engineering trade study to examine the application of a new design for Spectrum’s technology in certain mobile devices, including smartphones. The engineering trade study is the first step towards the development of a prototy…

What Happened to NexOptic Technology Corp?

Last week, we witnessed a roller coaster ride in one of our largest holdings, NexOptic Technology (NXO). Here’s the scoop on what happened, as we explain the tactics of how big money firms short stocks. But don’t tell anyone, it’s supposed to be a secret……

Flattening the Telescope — NexOptic to Unveil Blade Optics™ Prototype on April 4th

NexOptic Technology Corp. and Spectrum Optix Inc. are about to announce a major breakthrough at a media event to be held at the H.R. MacMillan Space Centre in Vancouver, British Columbia.The theme of the evening is “Flattening the Telescope,” and will mark the Companies’ first step in transforming what they believe may redefine many additional optical applications by utilizing th…

50/50: A Perfect Pilot Study from 3D Signatures on Blood-Based Prostate Cancer

3D Signatures Inc. just told the world that the results of a prospective blood-based prostate cancer pilot study using the Company’s proprietary TeloViewTM software platform was a perfect 50/50. Based on blinded blood samples, TeloViewTM correctly predicted the stability and aggressiveness of disease for each of the study’s 50 intermediate risk prostate cancer patients.…